Lessons from the biology of CETP inhibition10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD - Amsterdam, The Netherlands
Video navigation menu
- CETP inhibition, atherogenic lipoproteins and CHD risk 0:50
- CETP inhibition biology 4:02
- Lessons from previous CETP inhibitor outcome trials 4:52
This presentation by Prof. Kastelein is first lecture of an educational series about CETP inhibitors.
Prof. John Kastelein, MD, PhD – Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, The Netherlands.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from New Amsterdam Pharma.